Evidence map›Paper›PMID 29519868›Full record

ArticleHaematologica2018

RON kinase inhibition reduces renal endothelial injury in sickle cell disease mice.

Alfia Khaibullina, Elena A Adjei, Nowah Afangbedji, Andrey Ivanov, Namita Kumari, Luis E F Almeida, Zenaide M N Quezado, Sergei Nekhai, Marina Jerebtsova

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Sickle Cell Disease and CKD: An Update.American journal of nephrology · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. RON Expression Mediates Lipopolysaccharide-Mediated Dendritic Cell MaturationFrontiers in cellular and infection microbiology · 2020
    Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alfia KhaibullinaCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Elena A AdjeiCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Nowah AfangbedjiCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Andrey IvanovCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Namita KumariCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Luis E F AlmeidaDepartment of Perioperative Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Zenaide M N QuezadoDepartment of Perioperative Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Sergei NekhaiCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Marina JerebtsovaDepartment of Microbiology, College of Medicine, Howard University, Washington, DC, USA marina.jerebtsova@howard.edu.
Howard University · USNational Institutes of Health Clinical Center · US

Funding

SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI MICHAEL Ilya BUKRINSKY · 2015 to 2026
$29.6M
PROTEOMICS CORE FACILITYG12MD007597 · NIMHD · HOWARD UNIVERSITY · PI SOUTHERLAND, WILLIAM M. · 2012 to 2018
$14.8M
Center for Hemoglobin Research in Minorities (CHaRM)P50HL118006 · NHLBI · HOWARD UNIVERSITY · PI NEKHAI, SERGEI · 2013 to 2017
$7.0M
Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African AmericansR01HL125005 · NHLBI · HOWARD UNIVERSITY · PI MARINA A JEREBTSOVA, SERGEI NEKHAI · 2014 to 2026
$6.7M
Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammationR41MD008829 · NIMHD · REVERAGEN BIOPHARMA, INC. · PI DAMSKER, JESSE, QUEZADO, ZENAIDE MARIA · 2014 to 2014
$225k
Neurobiology of pain and behavior changes associated with rare diseases and developmental disabilitiesZIACL090052 · CLC · CLINICAL CENTER · PI QUEZADO, ZENAIDE · 2017 to 2025
$0k
Pathobiology of pain in sickle cell diseaseZIACL090053 · CLC · CLINICAL CENTER · PI QUEZADO, ZENAIDE · 2017 to 2025
$0k
Development of novel strategies for the treatment of pain in childrenZIACL090054 · CLC · CLINICAL CENTER · PI QUEZADO, ZENAIDE · 2017 to 2025
$0k
NHLBI NIH HHS P50 HL118006NHLBI NIH HHS R01 HL125005NIAID NIH HHS P30 AI117970NIMHD NIH HHS G12 MD007597NIMHD NIH HHS R41 MD008829
6 · The paper itself

Abstract

Sickle cell disease patients are at increased risk of developing a chronic kidney disease. Endothelial dysfunction and inflammation associated with hemolysis lead to vasculopathy and contribute to the development of renal disease. Here we used a Townes sickle cell disease mouse model to examine renal endothelial injury. Renal disease in Townes mice was associated with glomerular hypertrophy, capillary dilation and congestion, and significant endothelial injury. We also detected substantial renal macrophage infiltration, and accumulation of macrophage stimulating protein 1 in glomerular capillary. Treatment of human cultured macrophages with hemin or red blood cell lysates significantly increased expression of macrophage membrane-associated protease that might cleave and activate circulating macrophage stimulating protein 1 precursor. Macrophage stimulating protein 1 binds to and activates RON kinase, a cell surface receptor tyrosine kinase. In cultured human renal glomerular endothelial cells, macrophage stimulating protein 1 induced RON downstream signaling, resulting in increased phosphorylation of ERK and AKT kinases, expression of Von Willebrand factor, increased cell motility, and re-organization of F-actin. Specificity of macrophage stimulating protein 1 function was confirmed by treatment with RON kinase inhibitor BMS-777607 that significantly reduced downstream signaling. Moreover, treatment of sickle cell mice with BMS-777607 significantly reduced glomerular hypertrophy, capillary dilation and congestion, and endothelial injury. Taken together, our findings demonstrated that RON kinase is involved in the induction of renal endothelial injury in sickle cell mice. Inhibition of RON kinase activation may provide a novel approach for prevention of the development of renal disease in sickle cell disease.

Indexed as

AminopyridinesAnemia, Sickle CellAnimalsCells, CulturedEndothelium, VascularHumansKidneyMacrophagesMicePyridonesReceptor Protein-Tyrosine KinasesAminopyridinesN-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamidePyridonesReceptor Protein-Tyrosine KinasesRON protein

Identifiers

PMID29519868
PMCPMC5927980
OpenAlexW2794377062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.